semaglutide etf Novo cuts GLP-1 prices 70%, but revenue could grow in 2026 Chinese companies turn to generics

The physiological difference between those two scenarios is enormous particularly for someone whose estimated BAC is near the legal threshold

Patients dependent on Wegovy for metabolic support must navigate unpredictable refill windows, insurance coverage denials, and geographic availability variationschallenges that compound the difficulty of maintaining a therapeutic GLP-1 regimen

The Semaglutide cardiOvascular oUtcomes triaL (SOUL) recruited 9,650 people for the study who have pre-existing cardiovascular disease, such as coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular disease, and/or chronic kidney disease

The compound can dramatically shorten recovery time between workouts

RobinsonLEHoltTAReesKRandevaHSOHareJP